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Summary
 
Crry (complement receptor 1–related protein/gene y) is a key cellular complement regulator in
rodents. It is also present in Fx1A, the renal tubular preparation used to immunize rats to in-
duce active Heymann nephritis (HN), a model of membranous nephropathy. We hypothesized
that rats immunized with anti-Fx1A develop autoantibodies (auto-Abs) to Crry as well as to the
megalin-containing HN antigenic complex, and that anti-Crry Abs promote the development
of injury in HN by neutralizing the complement regulatory activity of Crry. Rats immunized
with Fx1A lacking Crry remained free of proteinuria and glomerular deposits of C3 during a
10-wk follow-up despite typical granular immunoglobulin (Ig)G deposits in glomeruli. Anti-
Fx1A auto-Abs were present in their sera at levels that were not different from sera pooled
from proteinuric rats with HN induced with nephritogenic Fx1A. Passive administration of
sheep anti-Crry Abs to rats immunized with Crry-deficient Fx1A led to proteinuria and glom-
erular C3 deposition, which were not seen in such rats injected with preimmune IgG, nor in
rats with collagen-induced arthritis injected with anti-Crry IgG. To directly examine the role
of Crry in HN, rats were immunized with Crry-deficient Fx1A reconstituted with rCrry. This
led to typical HN, with 8 out of 15 rats developing proteinuria within 14 wk. Moreover, the
extent of glomerular C3 deposition correlated with proteinuria, and anti-Crry Abs were
present in glomerular eluates. Thus, Crry is a key nephritogenic immunogen in Fx1A. Forma-
tion of neutralizing auto-Abs to Crry impairs its function, leading to unrestricted complement
activation by Abs reactive with the HN antigenic complex on the epithelial cell surface.
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H
 
eymann nephritis (HN)
 
1
 
 is a widely studied model of
membranous nephropathy with many similarities to
 
the human disease (1, 2). Active immunization of suscepti-
ble rat strains with fraction 1A (Fx1A), a crude renal tubu-
lar preparation, induces the production of IgG auto-Abs
that accumulate in glomeruli. Within 8 wk of immuniza-
tion with Fx1A, 
 
z
 
60% of animals develop proteinuria,
which is associated with glomerular deposition of C3 and
C5b-9 (3, 4). As shown in passive HN, heterologous anti-
Fx1A, when injected into rats, reacts with antigens on the
glomerular epithelial cell surface and activates complement.
In this model, the assembly of C5b-9 on glomerular epi-
thelial cell membranes is directly pathogenic (5–7). Similar
mechanisms are presumed to be operative in active HN.
Much effort has gone into identifying the antigen(s) con-
tained within Fx1A that confer pathogenic potential to this
immunogen. One well-described antigen was originally
termed gp330 and is now known as megalin (8–10). Active
immunization with megalin, or passive administration of
anti-megalin Ab, leads to glomerular deposition of immune
complexes. Yet despite the accumulation of IgG Ab in im-
mune deposits, there is no glomerular C3 or C5b-9 deposi-
tion and animals do not develop abnormal proteinuria (2, 11).
Crry (complement receptor 1-related protein/gene y) is
a rodent complement inhibitor that combines the functions
of human decay-accelerating factor (CD55) and membrane
cofactor protein (CD46). Although not a true genetic ho-
mologue, Crry is considered a functional analogue of these
two proteins, and is widely expressed (12–17). Not surpris-
 
1
 
Abbreviations used in this paper:
 
 CIA, collagen-induced arthritis; Crry,
complement receptor 1-related protein/gene y; HN, Heymann nephritis;
IF, immunofluorescence.
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ingly, given that Fx1A is a crude extract of renal tubules
which contain Crry (18, 19), heterologous anti-Fx1A Abs
contain reactivity towards Crry. These Abs inhibit the
function of Crry in cultured glomerular epithelial cells
leading to unrestricted complement activation (20, 21).
Since Crry is contained in Fx1A, we were interested
in determining if autoAbs were generated to Crry and
whether these were of pathogenic importance in HN. In
this study, animals immunized with Fx1A lacking Crry did
not develop abnormal proteinuria or glomerular C3 depo-
sition despite the formation of anti-Fx1A Abs, which
formed typical glomerular subepithelial deposits. Nephrito-
genicity of this preparation could be reconstituted by pas-
sive transfer of anti-Crry Abs or by inclusion of rCrry in
the immunogen.
 
Materials and Methods
 
Fx1A and rCrry.
 
Fx1A was prepared from normal Sprague-
Dawley rat kidneys by standard techniques (1). One batch was
made from freshly isolated Sprague-Dawley rat kidneys, which
led to typical HN upon active immunization of Lewis rats. The
second Fx1A preparation was isolated from commercially ob-
tained Sprague-Dawley rat kidneys (Pel-Freez Biologicals, Rog-
ers, AR). This failed to induce classic disease manifestations of
HN, the reasons for which are studied here.
The five NH
 
2
 
-terminal short consensus repeats of Crry (22,
23) containing the active sites of Crry were produced as a recom-
binant soluble protein in 
 
Pichia pastoris
 
. rCrry was purified by se-
quential Mono Q and Mono
 
 
 
P
 
 
 
chromatography (Amersham
Pharmacia Biotech, Piscataway, NJ; reference 24).
 
Anti-Crry Abs.
 
Serum was obtained from a single sheep hy-
perimmunized with rCrry. IgG was isolated by protein G affinity
chromatography (Amersham Pharmacia Biotech). Preimmune
IgG from the same sheep was used as a control in these studies.
Anti-Crry F(ab
 
9
 
)
 
2
 
 was generated by pepsin treatment followed by
size exclusion chromatography on a Sephacryl S-100HR column.
No intact heavy chains were present by SDS-PAGE under reduc-
ing conditions.
 
Animal Studies.
 
HN was induced by immunizing 150-g fe-
male Lewis rats with Fx1A. 10 mg of Fx1A was mixed with 4 mg
of 
 
Mycobacterium butyricum
 
 in 0.1 ml of PBS and emulsified with
an equivalent volume of complete Freund’s adjuvant (Difco, De-
troit, MI), which was injected in equally divided doses into both
hind footpads. Starting 6 wk after immunization, animals were
housed biweekly in metabolic cages for urine collection. Sera
were obtained at death by cardiac puncture. Renal tissue was ob-
tained by survival renal biopsy and at death.
To have controls with an actively produced autoimmune dis-
ease, collagen-induced arthritis (CIA) was induced contempora-
neously in Lewis rats. These animals were immunized with 0.2 mg
of bovine type II collagen (Sigma Chemical Co., St. Louis, MO)
in incomplete Freund’s adjuvant twice over 7 d (25). This re-
sulted in a polyarticular arthritis, which peaked in severity by 4 wk
after immunization and then resolved.
Passive administration of anti-Crry Abs was performed by in-
jecting animals with 10 mg of anti-Crry IgG or F(ab
 
9
 
)
 
2
 
 intrave-
nously given in divided doses over 2 d. Control animals received
10 mg of preimmune IgG intravenously over 2 d.
 
Measures of Disease.
 
Urinary protein excretion was measured
by a sulfosalicyclic acid precipitation method (26). Proteinuria
was considered abnormal when excretion was 
 
$
 
6 mg/d (1). Di-
rect immunofluorescence (IF) was performed on cryostat sections
for rat IgG and C3 (26). Semiquantitative scores for IF staining
intensity were assigned to coded sections (27).
To measure glomerular anti-Fx1A and anti-Crry Abs, glomer-
uli were isolated from one kidney by sieving (6), after which Abs
were eluted by sonication in 20 mM of citric acid, pH 3.2, in the
presence of protease inhibitors (11). Glomerular protein content
was determined by a bicinchoninic acid assay (Pierce Chemical
Co., Rockford, IL).
 
ELISA.
 
ELISAs for anti-Fx1A and anti-Crry Abs were per-
formed by coating polystyrene plates with 10 
 
m
 
g/ml detergent-
solubilized Fx1A or rCrry. Diluted sera or glomerular eluates
were added, which were detected with peroxidase-conjugated
anti-rat IgG (Sigma Chemical Co.), followed by development
with 
 
o
 
-phenylene-diamine. Measurements were made at OD
 
450
 
,
and data are presented as OD
 
450
 
 U/ml. When comparisons were
made, samples were run in duplicates on a single ELISA plate. For
measurements of Crry, polystyrene plates were coated with 20
 
m
 
g/ml of anti-Crry IgG, after which serial dilutions of rCrry or
detergent-solubilized Fx1A were added. Bound Crry was de-
tected with biotinylated anti-Crry, followed by streptavidin–
horseradish peroxidase. The ELISA was sensitive to 10 ng/ml
Crry.
 
Statistics.
 
Statistical analyses were performed with Minitab
software (College Park, MD). Data are expressed as mean 
 
6
 
 SEM
and were analyzed by Student’s 
 
t
 
 test when two groups were
compared or by analysis of variance for multiple groups.
 
Results
 
Two preparations of Fx1A were compared in our stud-
ies. These preparations differed in their capacity to induce
classic HN, as defined by the development of abnormal
proteinuria in the majority of animals starting 6–8 wk after
immunization. The nephritogenic preparation of Fx1A iso-
lated from freshly obtained kidneys contained 3.1% Crry
(wt/wt), whereas the Fx1A that was prepared from freeze-
thawed kidneys failed to induce disease manifestations of
HN and lacked Crry by a sensitive ELISA. These results
suggested that Crry was an important component in
nephritogenic Fx1A.
The Fx1A preparation lacking Crry was further studied
through the active immunization of 12 female Lewis rats.
Animals were followed for 10 wk, during which time no
significant proteinuria occurred (0.98 
 
6
 
 0.12 and 2.14 
 
6
 
0.53 mg/d at 6 and 10 wk, respectively, after immuniza-
tion). At this time, all animals underwent renal biopsy. By
IF microscopy there was strongly positive granular staining
for IgG outlining glomerular capillary walls in 10 out of 12
animals (Fig. 1 
 
A
 
), whereas the remaining 2 animals had
only faintly apparent IgG deposits. In all animals, character-
istic deposits of C3 were absent (Fig. 1 
 
B
 
).
To test if the absence of C3 deposits and proteinuria in
HN rats immunized with Crry-deficient Fx1A was due to
preservation of glomerular Crry complement regulatory ac-
tivity, function-neutralizing anti-Crry Abs were adminis-
tered passively. HN animals received either anti-Crry IgG
or preimmune IgG as a control 10 wk after immunization
with Crry-deficient Fx1A. For these studies, the 10 animals 
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with strongly positive glomerular IgG staining were used.
To exclude an effect of anti-Crry IgG to activate the classi-
cal pathway, anti-Crry F(ab
 
9
 
)
 
2
 
 was also used in these stud-
ies. As further controls, Lewis rats in which CIA had been
induced 10 wk earlier were injected with anti-Crry IgG.
HN animals injected with anti-Crry had a progressive rise
in urinary protein which peaked 5 d after Ab injection,
with five out of seven animals developing abnormal pro-
teinuria (Fig. 2). In contrast, there was no significant pro-
teinuria in either HN rats injected with preimmune IgG or
CIA rats injected with anti-Crry IgG. In the three animals
with heavy proteinuria (
 
.
 
60 mg/d), there was strong stain-
ing for C3 by IF microscopy in glomeruli (Fig. 1 
 
D
 
),
whereas the remaining animals with 
 
,
 
60 mg/d proteinuria
continued to have absent C3 staining (Fig. 1 
 
C
 
).
To determine whether absence of Crry affected Ab pro-
duction to Fx1A, anti-Fx1A Abs were measured in sera of
rats immunized with Fx1A lacking Crry. These were
present before anti-Crry injection (4.12 
 
6
 
 0.55 OD
 
450
 
 U/ml)
and were not different from anti-Fx1A levels in pooled sera
from animals with active HN induced with nephritogenic
Fx1A (4.72 OD
 
450
 
 U/ml). Anti-Crry Abs were also detect-
able (2.22 OD
 
450
 
 U/ml) in these latter sera, whereas in ani-
mals immunized with anti-Fx1A lacking Crry, anti-Crry
levels were not significantly different from background
(0.18 
 
6
 
 0.12 OD
 
450
 
 U/ml). Thus, immunization of ani-
mals with an anti-Fx1A preparation lacking Crry leads to
the production of anti-Fx1A Abs that deposit in glomeruli.
Yet complement activation and proteinuria do not occur.
Neutralization of Crry function via the passive administra-
tion of anti-Crry Abs can lead to complement activation
and proteinuria in the presence of these glomerular-bound
IgG Abs.
These results suggested that generation of an immune re-
sponse to Crry is necessary for the development of pro-
teinuria in HN. The next set of studies directly tested
whether reconstituting Fx1A lacking Crry with rCrry
could restore nephritogenicity. Therefore, female Lewis
rats were immunized with Fx1A lacking Crry (
 
n
 
 
 
5 
 
20) or
with this same Fx1A preparation to which 0.5 mg of rCrry
was added (
 
n
 
 
 
5 
 
15). Animals were observed for 14 wk to
ensure that the potential development of proteinuria was
not missed. As in the previous studies, animals immunized
with Fx1A lacking Crry did not develop proteinuria (Fig.
3). In contrast, in animals immunized with Fx1A reconsti-
tuted with rCrry there was progressive development of
proteinuria, such that by 14 wk after immunization, 8 out
of 15 animals had significant proteinuria. This proportion
of proteinuric rats is very similar to that typically seen in ac-
tive HN (1). At death, anti-Fx1A Ab levels were compara-
ble in both groups (2.17 
 
6
 
 0.23 and 2.17 
 
6
 
 0.28 OD
 
450
 
U/ml).
In both groups of animals there was granular glomerular
IgG staining by IF microscopy, yet in the animals immu-
nized with Fx1A lacking Crry there was no glomerular C3
deposition. In contrast, animals immunized with Fx1A plus
rCrry had glomerular C3 deposition. Furthermore, the
semiquantitative score for C3 immunostaining correlated
with proteinuria (
 
r
 
 
 
5 
 
0.80,
 
 P 
 
, 
 
0.001), suggesting that
complement activation within glomeruli was pathogenic.
Anti-Crry Abs were present in glomerular eluates of rats
immunized with Fx1A plus rCrry (0.71 
 
6
 
 0.19 OD
 
450
 
 U/
 
m
 
g
glomerular protein). As expected, anti-Crry Abs were not
present in glomeruli of rats immunized with the Fx1A
Figure 1. Representative IF micrographs in animals immunized with
Fx1A lacking Crry. 10 wk after immunization, renal biopsies were per-
formed and tissue was stained for IgG (A) and C3 (B). Animals were then
injected with preimmune IgG (C) or anti-Crry IgG (D). 6 d later, animals
were killed and renal tissue was stained for C3 (C and D). The IF micro-
graphs shown in A, B, and D are from the same animal, and show typical
granular staining for IgG in HN (A) and the appearance of a similar stain-
ing pattern for C3 only after injection of anti-Crry IgG (D).
Figure 2. Effect of anti-Crry on urinary protein excretion in active
HN. Animals were immunized with Fx1A lacking Crry (Active Heymann
Nephritis) or with bovine type II collagen (CIA). 10 wk later, 5 mg of
anti-Crry IgG or F(ab9)2, or preimmune IgG, were injected intravenously
twice over a period of 24 h. 5 d after intravenous injection, urine was col-
lected and urinary protein was measured by the sulfosalicyclic acid precip-
itation method (1). Proteinuria was considered abnormal when $6 mg/d
(horizontal dashed line). Data for individual animals are shown. P 5 0.022
by one-way analysis of variance. 
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preparation lacking Crry (0.06 
 
6
 
 0.05 OD
 
450
 
 U/
 
m
 
g glo-
merular protein, which is not significantly different from
background). Thus, in HN, active immunization with
Fx1A containing Crry leads to formation of anti-Crry Abs
that deposit in glomeruli.
 
Discussion
 
In this study we show that rats immunized with Fx1A
lacking Crry do not develop proteinuria or C3 deposition
in glomeruli, despite the generation of anti-Fx1A Abs that
deposit in glomeruli. If Abs to Crry are reconstituted either
via the passive administration of anti-Crry Abs or by the in-
clusion of rCrry in the immunogen, animals develop pro-
teinuria to the extent and level seen in active HN induced
with Crry-containing Fx1A. These findings show that Crry
is a critical immunogen within Fx1A and is essential for its
nephritogenic effect. Formation of Abs to Crry impairs the
function of this intrinsic complement regulator. Since Crry
is the key regulator of complement at the C3/C5 conver-
tase stage, inhibition of its function leads to unrestricted
complement activation. As shown in the passive HN
model of membranous nephropathy, complement activa-
tion on the glomerular epithelial cell results in injury of this
cell and impairment of the glomerular permselectivity bar-
rier to the passage of protein.
In our past studies, we found that heterologous anti-
Fx1A Abs reacted with glomerular epithelial cell antigens
and could activate complement on the surface of these
cells, leading to cellular injury (6). Subsequently, we ob-
served that nephritogenic anti-Fx1A impaired intrinsic
complement regulation in glomerular epithelial cells. Such
an effect occurred at the level of complement C3/C5 con-
vertases formed from either the classical or alternative path-
ways (20). At that time, the antigen responsible for these
effects of anti-Fx1A was unknown. With the isolation of
rat Crry as the antigen reactive with mAb 5I2 (28), it was
possible to prove that anti-Fx1A reacted with rat Crry,
consistent with its inhibiting intrinsic regulation of C3/C5
convertases (21). That heterologous anti-Fx1A Abs contains
reactivity towards Crry is not surprising, given the wide-
spread distribution of Crry, including in renal tubules (18,
19). Interestingly, we have also shown that heterologous
anti-Fx1A has reactivity towards CD59, a regulator of
C5b-9 formation, which can similarly be attributed to the
presence of CD59 in renal tubular cells (18). The role for
reactivity of heterologous anti-Fx1A with Crry or CD59 in
passive HN is a subject of ongoing study.
Despite the identification of megalin as an unquestion-
ably important immunogen within Fx1A, it is very clear
that megalin is not the only nephritogenic component con-
tained within Fx1A. Thus, either passive administration of
antimegalin Ab or active immunization with megalin is in-
sufficient to recapitulate the full disease of HN. This has
stimulated a continuing search for additional antigenic
component(s). A number of candidate antigens have been
identified, including 
 
b
 
1 integrins, dipeptidyl peptidase IV,
aminopeptidase A, and an uncharacterized lipid antigen
(29–31).
Although HN has many similarities to human membra-
nous nephropathy, identifying target human antigens in
this disease has proved elusive. For instance, as yet there is
no identified analogue to megalin or the HN antigenic
complex expressed in human glomeruli (8–10, 32). Human
glomerular epithelial cells contain decay-accelerating factor
and membrane cofactor protein (33, 34), which together
contain the function of Crry. There are subepithelial IgG
deposits in human membranous nephropathy, exactly as in
HN. The evidence for the complement mediation of this
disease in humans is strong. There is glomerular deposition
of C3 and C5b-9, and the appearance of C5b-9 in the
urine has prognostic importance (35–37). An intriguing
possibility raised by these studies is that autoAbs to decay-
accelerating factor and/or to membrane cofactor protein
may form and accumulate in human membranous nephrop-
athy. If so, it may be possible, with the use of recombinant
complement regulators (38–42) to overcome the effects of
these autoAbs and thereby prevent glomerular epithelial
cell injury and proteinuria.
 
We thank Dr. Andrew Minto for preparing Fx1A.
This work was supported by National Institutes of Health grants DK30932 (to D.J. Salant) and DK41873 (to
R.J. Quigg), and by a grant-in-aid from the National Kidney Foundation, Illinois Chapter (to R.J. Quigg).
J.J. Alexander was supported by training grant DK07510 from the National Institutes of Health.
Figure 3. Urinary protein excretion over time in animals immunized
with Fx1A lacking Crry (Fx1A - rCrry, d) or immunized with this iden-
tical preparation reconstituted with rCrry (Fx1A 1 rCrry, s). Data for
individual animals are shown. Proteinuria was considered abnormal when
$6 mg/d (horizontal dashed line). At 14 wk after immunization, urinary
protein excretion was 42.4 6 13.5 and 1.4 6 0.3 mg/d in animals immu-
nized with Fx1A with and without rCrry, respectively (mean 6 SEM;
P , 0.001 by Student’s t testing). 
1357
 
Schiller et al.
Address correspondence to Richard Quigg, The University of Chicago, 5841 South Maryland Ave.,
MC5100, Chicago, IL 60637. Phone: 773-702-0757; Fax: 773-702-4816; E-mail: rquigg@medicine.
bsd.uchicago.edu
 
Received for publication 22 June 1998.
 
References
 
1. Salant, D.J., and A.V. Cybulsky. 1988. Experimental glomer-
ulonephritis. 
 
Methods Enzymol.
 
 162:421–461.
2. Kerjaschki, D., and T.J. Neale. 1996. Molecular mechanisms
of glomerular injury in rat experimental membranous nephrop-
athy (Heymann nephritis). J. Am. Soc. Nephrol. 7:2518–2526.
3. Salant, D.J., S. Belok, M.P. Madaio, and W.G. Couser. 1980.
A new role for complement in experimental membranous
nephropathy in rats. J. Clin. Invest. 66:1339–1350.
4. Makker, S.P. 1993. Analysis of glomeruli-eluted Gp330 au-
toantibodies and of Gp330 antigen of Heymann nephritis. J.
Immunol. 151:6500–6508.
5. Cybulsky, A.V., H.G. Rennke, I.D. Feintzeig, and D.J. Sal-
ant. 1986. Complement-induced glomerular epithelial cell
injury: role of the membrane attack complex in rat membra-
nous nephropathy. J. Clin. Invest. 77:1096–1107.
6. Quigg, R.J., A.V. Cybulsky, J.B. Jacobs, and D.J. Salant.
1988. Anti-Fx1A produces complement-dependent cytotox-
icity of glomerular epithelial cells. Kidney Int. 34:43–52.
7. Baker, P.J., R.F. Ochi, M. Schulze, R.J. Johnson, C. Camp-
bell, and W.G. Couser. 1989. Depletion of C6 prevents de-
velopment of proteinuria in experimental membranous ne-
phropathy in rats. Am. J. Pathol. 135:185–194.
8. Kerjaschki, D., and M.G. Farquhar. 1982. The pathogenic
antigen of Heymann nephritis is a membrane glycoprotein of
the renal proximal tubule brush border. Proc. Natl. Acad. Sci.
USA. 79:5557–5581.
9. Pietromonaco, S., D. Kerjaschki, S. Binder, R. Ullrich, and
M.G. Farquhar. 1990. Molecular cloning of a cDNA encod-
ing a major pathogenic domain of the Heymann nephritis an-
tigen gp330. Proc. Natl. Acad. Sci. USA. 87:1811–1815.
10. Farquhar, M.G., A. Saito, D. Kerjaschki, and R.A. Orlando.
1995. The Heymann nephritis antigenic complex: megalin
(gp330) and RAP. J. Am. Soc. Nephrol. 6:35–47.
11. Raychowdhury, R., G. Zheng, D. Brown, and R.T. Mc-
Cluskey. 1996. Induction of Heymann nephritis with a
gp330/megalin fusion protein. Am. J. Pathol. 148:1613–
1623.
12. Wong, W., and D.T. Fearon. 1985. p65: a C3b-binding pro-
tein on murine cells that shares antigenic determinants with
the human C3b receptor (CR1) and is distinct from murine
C3b receptor. J. Immunol. 134:4048–4056.
13. Paul, M.S., M. Aegerter, S.E. O’Brien, C.B. Kurtz, and J.H.
Weis. 1989. The murine complement receptor gene family.
I. Analysis of mCRY gene products and their homology to
human CR1. J. Immunol. 142:582–589.
14. Foley, S., B. Li, M. Dehoff, H. Molina, and V.M. Holers.
1993. Mouse Crry/p65 is a regulator of the alternative path-
way of complement activation. Eur. J. Immunol. 23:1381–
1384.
15. Li, B., C. Sallee, M. Dehoff, S. Foley, H. Molina, and V.M.
Holers. 1993. Mouse Crry/p65: Characterization of mono-
clonal antibodies and the tissue distribution of a functional
homologue of human MCP and DAF. J. Immunol. 151:4295–
4305.
16. Kim, Y.-U., T. Kinoshita, H. Molina, D. Hourcade, T. Seya,
L.M. Wagner, and V.M. Holers. 1995. Mouse complement
regulatory protein Crry/p65 uses the specific mechanisms of
both human decay-accelerating factor and membrane cofac-
tor protein. J. Exp. Med. 181:151–159.
17. Quigg, R.J., B.P. Morgan, V.M. Holers, S. Adler, A.E.
Sneed, and C.F. Lo. 1995. Complement regulation in the rat
glomerulus: Crry and CD59 regulate complement in glomer-
ular mesangial and endothelial cells. Kidney Int. 48:412–421.
18. Funabashi, K., N. Okada, S. Matsuo, T. Yamamoto, B.P.
Morgan, and H. Okada. 1994. Tissue distribution of comple-
ment regulatory membrane proteins in rats. Immunology. 81:
444–451.
19. Nomura, A., K. Nishikawa, Y. Yuzawa, H. Okada, N.
Okada, B.P. Morgan, S.J. Piddlesden, M. Nadai, T. Hase-
gawa, and S. Matsuo. 1995. Tubulointerstitial injury induced
in rats by a monoclonal antibody which inhibits function of a
membrane inhibitor of complement. J. Clin. Invest. 96:2348–
2356.
20. Quigg, R.J., A.V. Cybulsky, and D.J. Salant. 1991. Effect of
nephritogenic antibody on complement regulation in cul-
tured rat glomerular epithelial cells. J. Immunol. 147:838–845.
21. Quigg, R.J., V.M. Holers, B.P. Morgan, and A.E. Sneed.
1995. Crry and CD59 regulate complement in rat glomerular
epithelial cells and are inhibited by the nephritogenic anti-
body of passive Heymann nephritis. J. Immunol. 154:3437–
3443.
22. Sakurada, C., H. Seno, N. Dohi, H. Takizawa, M. Nonaka,
N. Okada, and H. Okada. 1994. Molecular cloning of the rat
complement regulatory protein, 5I2 antigen. Biochem. Bio-
phys. Res. Commun. 198:819–826.
23. Quigg, R.J., C.F. Lo, J.J. Alexander, A.E. Sneed, and G.
Moxley. 1995. Molecular characterization of rat Crry: wide-
spread distribution of two alternative forms of Crry mRNA.
Immunogenetics. 42:362–367.
24. He, C., J.J. Alexander, A. Lim, and R.J. Quigg. 1997. Pro-
duction of the rat complement regulator, Crry, as an active
soluble protein in Pichia pastoris. Arch. Biochem. Biophys. 341:
347–352.
25. Ridge, S.C., A.L. Oronsky, and S.S. Kerwar. 1988. Type II
collagen-induced arthritis in rats. Methods Enzymol. 162:
355–360.
26. Quigg, R.J., D.R. Abrahamson, A.V. Cybulsky, J. Badala-
menti, A.W.M. Minto, and D.J. Salant. 1989. Studies with
antibodies to cultured rat glomerular epithelial cells: subepi-
thelial immune deposit formation after in vivo injection. Am.
J. Pathol. 134:1125–1133.
27. Quigg, R.J., A. Lim, M. Haas, J.J. Alexander, C. He, and
M.C. Carroll. 1998. Immune complex glomerulonephritis in
C4- and C3-deficient mice. Kidney Int. 53:320–330.
28. Takizawa, H., N. Okada, and H. Okada. 1994. Complement
inhibitor of rat cell membrane resembling mouse Crry/p65.
J. Immunol. 152:3032–3038.
29. Adler, S., and X. Chen. 1992. Anti-Fx1A antibody recog-
nizes a b1-integrin on glomerular epithelial cells and inhibits
adhesion and growth. Am. J. Physiol. 262:F770–F776.1358 Inhibition of Complement Regulation in Heymann Nephritis
30. Susani, M., M. Schulze, M. Exner, and D. Kerjaschki. 1994.
Antibodies to glycolipids activate complement and promote
proteinuria in passive Heymann nephritis. Am. J. Pathol. 144:
807–819.
31. Salant, D.J., Y. Natori, and F. Shimizu. 1997. Glomerular in-
jury due to antibody alone. In Immunologic Renal Diseases.
E.G. Neilson and W.G. Couser, editors. Lippincott-Raven,
Philadelphia. 359–375.
32. Raychowdhury, R., J.L. Niles, R.T. McCluskey, and J.A.
Smith. 1989. Autoimmune target in Heymann nephritis is a
glycoprotein with homology to the LDL receptor. Science.
244:1163–1165.
33. Quigg, R.J., A. Nicholson-Weller, A.V. Cybulsky, J. Badala-
menti, and D.J. Salant. 1989. Decay accelerating factor regu-
lates complement activation on glomerular epithelial cells. J.
Immunol. 142:877–882.
34. Nakanishi, I., A. Moutabarrik, T. Hara, M. Hatanaka, T. Ha-
yashi, T. Syouji, N. Okada, E. Kitamura, Y. Tsubakihara, M.
Matsumoto, and T. Seya. 1994. Identification and character-
ization of membrane cofactor protein (CD46) in the human
kidneys. Eur. J. Immunol. 24:1529–1535.
35. Hinglais, N., M.D. Kazatchkine, S. Bhakdi, M.D. Appay, C.
Mandet, J. Grossetete, and J. Bariety. 1986. Immunohis-
tochemical study of the C5b-9 complex of complement in
human kidneys. Kidney Int. 30:399–410.
36. Schulze, M., J.V. Donadio, Jr., C.J. Pruchno, P.J. Baker, R.J.
Johnson, R.A.K. Stahl, S. Watkins, D.C. Martin, R.
Wurzner, O. Gotze, and W.G. Couser. 1991. Elevated uri-
nary excretion of the C5b-9 complex in membranous nephrop-
athy. Kidney Int. 40:533–538.
37. Lehto, T., E. Honkanen, A.M. Teppo, and S. Meri. 1995.
Urinary excretion of protectin (CD59), complement SC5b-9
and cytokines in membranous glomerulonephritis. Kidney Int.
47:1403–1411.
38. Weisman, H.F., T. Bartow, M.K. Leppo, H.C. Marsh, Jr.,
G.R. Carson, M.F. Concino, M.P. Boyle, K.H. Roux, M.L.
Weisfeldt, and D.T. Fearon. 1990. Soluble human comple-
ment receptor type 1: in vivo inhibitor of complement sup-
pressing post-ischemic myocardial inflammation and necrosis.
Science. 249:146–151.
39. Kalli, K.R., P. Hsu, and D.T. Fearon. 1994. Therapeutic uses
of recombinant complement protein inhibitors. Springer
Semin. Immunopathol. 15:417–431.
40. Moore, F.D., Jr. 1994. Therapeutic regulation of the comple-
ment system in acute injury states. Adv. Immunol. 56:267–299.
41. Couser, W.G., R.J. Johnson, B.A. Young, C.G. Yeh, C.A.
Toth, and A.R. Rudolph. 1995. The effects of soluble re-
combinant complement receptor 1 on complement-mediated
experimental glomerulonephritis. J. Am. Soc. Nephrol. 5:
1888–1894.
42. Higgins, P.J., K. Jone-Long, R. Lobell, C. Sardonini, M.K.
Alessi, and C.G. Yeh. 1997. A soluble chimeric complement
inhibitory protein that possesses both decay-accelerating and
factor I cofactor activities. J. Immunol. 158:2872–2881.